Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Janette Greenhalgh,1* Adrian Bagust,1 Angela Boland,1 Kerry Dwan,1 Sophie Beale,1 Juliet Hockenhull,1 Christine Proudlove,2 Yenal Dundar,1 Marty Richardson,1 Rumona Dickson,1 Anna Mullard3 and Ernie Marshall3

1Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
2North West Medicines Information Centre, Pharmacy Practice Unit, Liverpool, UK
3The Clatterbridge Centre NHS Foundation Trust, Liverpool, UK

*Corresponding author

Declared competing interests of authors: Dr Anna Mullard has received hospitality from Roche (UK) Ltd.

Published June 2015
DOI: 10.3310/hta19470

Plain English summary

Erlotinib and gefitinib for treating non-small cell lung cancer
Health Technology Assessment 2015; Vol. 19: No. 47
DOI: 10.3310/hta19470

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Lung cancer is the second most common cancer in the UK, and in 2010 42,000 people in the UK were diagnosed with the disease. Over 75% of lung cancers are of a specific kind called non-small cell lung cancer (NSCLC). People with incurable NSCLC may be given treatment to control symptoms and improve quality of life. When initial treatments are no longer effective, patients who are well enough may receive a follow-on treatment. We considered the benefits and costs of two follow-on drug treatments, erlotinib [Tarceva®, Roche (UK) Ltd] and gefitinib (IRESSA®, AstraZeneca). We looked for evidence comparing these drugs with each other and with other current treatments (the drug docetaxel and supportive care). In this systematic review we identified 12 trials; seven compared the use of gefitinib with the use of docetaxel or supportive care, four compared the use of erlotinib with the use of docetaxel or supportive care and one trial compared the use of erlotinib with the use of gefitinib. We considered the evidence for three groups of people with NSCLC: people who tested positive for the epidermal growth factor receptor (EGFR) mutation, people who tested negative for the EGFR mutation and people who have not been tested or for whom the results of EGFR testing are unknown. For patients with the EGFR mutation, there was limited evidence and we could not determine the best treatment. For patients without the EGFR mutation, we found that the drug docetaxel had more benefits and lower costs than erlotinib, and that docetaxel also offered value for money to the NHS. For patients whose EGFR status is unknown, we found the use of erlotinib to be more effective than supportive care, but erlotinib did not offer value for money to the NHS.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 12/49/01. The protocol was agreed in March 2013. The assessment report began editorial review in November 2013 and was accepted for publication in October 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Greenhalgh et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:  www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact:  nihredit@southampton.ac.uk